Citations (38)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Avtar Singh Gautam, Shivam Kumar Pandey, Vaibhav Lasure, Sachin Dubey & Rakesh Kumar Singh. (2023) Monoclonal antibodies for the management of central nervous system diseases: clinical success and future strategies. Expert Opinion on Biological Therapy 23:7, pages 603-618.
Read now
Read now
Madia Lozupone, Vincenzo Solfrizzi, Francesca D’Urso, Ilaria Di Gioia, Rodolfo Sardone, Vittorio Dibello, Roberta Stallone, Angelo Liguori, Chiara Ciritella, Antonio Daniele, Antonello Bellomo, Davide Seripa & Francesco Panza. (2020) Anti-amyloid-β protein agents for the treatment of Alzheimer’s disease: an update on emerging drugs. Expert Opinion on Emerging Drugs 25:3, pages 319-335.
Read now
Read now
Koorosh Shahpasand, Alireza Sepehri Shamloo, Seyed Massood Nabavi, Kun Ping Lu & Xiao Zhen Zhou. (2018) “Tau immunotherapy: Hopes and hindrances”. Human Vaccines & Immunotherapeutics 14:2, pages 277-284.
Read now
Read now
Francesco Panza, Davide Seripa, Madia Lozupone, Vincenzo Solfrizzi, Bruno P. Imbimbo, Maria Rosaria Barulli, Rosanna Tortelli, Rosa Capozzo, Paola Bisceglia, Andrea Dimitri, Roberta Stallone, Vittorio Dibello, Nicola Quaranta, Antonio Daniele, Antonello Bellomo, Antonio Greco & Giancarlo Logroscino. (2018) The potential of solanezumab and gantenerumab to prevent Alzheimer’s disease in people with inherited mutations that cause its early onset. Expert Opinion on Biological Therapy 18:1, pages 25-35.
Read now
Read now
Francesco Panza, Davide Seripa, Vincenzo Solfrizzi, Bruno P. Imbimbo, Madia Lozupone, Antonio Leo, Rodolfo Sardone, Gaetano Gagliardi, Lucia Lofano, Bianca C. Creanza, Paola Bisceglia, Antonio Daniele, Antonello Bellomo, Antonio Greco & Giancarlo Logroscino. (2016) Emerging drugs to reduce abnormal β-amyloid protein in Alzheimer’s disease patients. Expert Opinion on Emerging Drugs 21:4, pages 377-391.
Read now
Read now
Daniela Galimberti & Elio Scarpini. (2016) Emerging amyloid disease-modifying drugs for Alzheimer’s disease. Expert Opinion on Emerging Drugs 21:1, pages 5-7.
Read now
Read now
Articles from other publishers (32)
Benjamin Ayodipupo Babalola, Oluwamayowa Samuel Akinsuyi, Elizabeth Oreoluwa Folajimi, Folakemi Olujimi, Ahmed Adebisi Otunba, Bruno Chikere, Ibitayo Ajayi Adewumagun & Tosin Emmanuel Adetobi. (2023) Exploring the future of SARS-CoV-2 treatment after the first two years of the pandemic: A comparative study of alternative therapeutics. Biomedicine & Pharmacotherapy 165, pages 115099.
Crossref
Crossref
David A. Loeffler. (2023) Antibody-Mediated Clearance of Brain Amyloid-β: Mechanisms of Action, Effects of Natural and Monoclonal Anti-Aβ Antibodies, and Downstream Effects. Journal of Alzheimer's Disease Reports 7:1, pages 873-899.
Crossref
Crossref
David A. Loeffler. (2023) Experimental approaches for altering the expression of Abeta‐degrading enzymes. Journal of Neurochemistry 164:6, pages 725-763.
Crossref
Crossref
Parth Sharma, Ritchu Babbar, Twinkle Sharma, Piyush Madaan, Sandeep Arora & Vishnu Nayak Badavath. (2023) Anti-Amyloid-β Immunotherapy: A Leading Novel Avenue for Alzheimer's
Disease. Mini-Reviews in Medicinal Chemistry 23:1, pages 53-66.
Crossref
Crossref
Haowen Qiao, Wen Zhao, Moujian Guo, Lili Zhu, Tao Chen, Jibo Wang, Xiaodong Xu, Zhentao Zhang, Ying Wu & Pu Chen. (2022) Cerebral Organoids for Modeling of HSV-1-Induced-Amyloid β Associated Neuropathology and Phenotypic Rescue. International Journal of Molecular Sciences 23:11, pages 5981.
Crossref
Crossref
Danko Jeremic, Lydia Jiménez-Díaz & Juan D. Navarro-López. (2021) Past, present and future of therapeutic strategies against amyloid-β peptides in Alzheimer’s disease: a systematic review. Ageing Research Reviews 72, pages 101496.
Crossref
Crossref
Morgan Robinson, Jennifer Lou, Banafsheh Mehrazma, Arvi Rauk, Michael Beazely & Zoya Leonenko. (2021) Pseudopeptide Amyloid Aggregation Inhibitors: In Silico, Single Molecule and Cell Viability Studies. International Journal of Molecular Sciences 22:3, pages 1051.
Crossref
Crossref
Jinpeng Lv, Ling Chen, Naping Zhu, Yindi Sun, Jianchun Pan, Jinsheng Gao, Jianwu Liu, Guangjun Liu & Yuanxiang Tao. (2020) Beta amyloid-induced time-dependent learning and memory impairment: involvement of HPA axis dysfunction. Metabolic Brain Disease 35:8, pages 1385-1394.
Crossref
Crossref
Jeffrey L. Cummings. (2020) Translational Scoring of Candidate Treatments for Alzheimer’s Disease: A Systematic Approach. Dementia and Geriatric Cognitive Disorders 49:1, pages 22-37.
Crossref
Crossref
Jeffrey Cummings, Howard H. Feldman & Philip Scheltens. (2019) The “rights” of precision drug development for Alzheimer’s disease. Alzheimer's Research & Therapy 11:1.
Crossref
Crossref
David S. Reynolds. (2019) A short perspective on the long road to effective treatments for Alzheimer's disease. British Journal of Pharmacology 176:18, pages 3636-3648.
Crossref
Crossref
Yannick Chantran, Jean Capron, Sonia Alamowitch & Pierre Aucouturier. (2019) Anti-Aβ Antibodies and Cerebral Amyloid Angiopathy Complications. Frontiers in Immunology 10.
Crossref
Crossref
Balazs Szatmari, Peter Balicza, Gyorgy Nemeth & Maria Judit Molnar. (2019) The Panomics Approach in Neurodegenerative Disorders. Current Medicinal Chemistry 26:10, pages 1712-1720.
Crossref
Crossref
Takeshi Iwatsubo, Atsushi Iwata, Kazushi Suzuki, Ryoko Ihara, Hiroyuki Arai, Kenji Ishii, Michio Senda, Kengo Ito, Takeshi Ikeuchi, Ryozo Kuwano, Hiroshi Matsuda, Chung‐Kai Sun, Laurel A. Beckett, Ronald C. Petersen, Michael W. Weiner, Paul S. Aisen & Michael C. Donohue. (2018) Japanese and North American Alzheimer's Disease Neuroimaging Initiative studies: Harmonization for international trials. Alzheimer's & Dementia 14:8, pages 1077-1087.
Crossref
Crossref
Stephen P. Salloway, Reisa Sperling, Nick C. Fox, Marwan N. Sabbagh, Lawrence S. Honig, Anton P. Porsteinsson, Hany Rofael, Nzeera Ketter, Daniel Wang, Enchi Liu, Stephen Carr, Ronald S. Black & H. Robert Brashear. (2018) Long-Term Follow Up of Patients with Mild-to-Moderate Alzheimer’s Disease Treated with Bapineuzumab in a Phase III, Open-Label, Extension Study. Journal of Alzheimer's Disease 64:3, pages 689-707.
Crossref
Crossref
Cassia Overk & Eliezer Masliah. (2018) Dale Schenk One Year Anniversary: Fighting to Preserve the Memories. Journal of Alzheimer's Disease 62:1, pages 1-13.
Crossref
Crossref
Anne-Claire Dupont, Bérenger Largeau, Denis Guilloteau, Maria Joao Santiago Ribeiro & Nicolas Arlicot. (2018) The Place of PET to Assess New Therapeutic Effectiveness in Neurodegenerative Diseases. Contrast Media & Molecular Imaging 2018, pages 1-15.
Crossref
Crossref
Chester A. Mathis, Brian J. Lopresti, Milos D. Ikonomovic & William E. Klunk. (2017) Small-molecule PET Tracers for Imaging Proteinopathies. Seminars in Nuclear Medicine 47:5, pages 553-575.
Crossref
Crossref
Youmei Wang, Tao Yan, Honghui Lu, Weiming Yin, Bin Lin, Weibin Fan, Xiaoli Zhang & Pedro Fernandez-Funez. (2017) Lessons from Anti-Amyloid-β Immunotherapies in Alzheimer Disease: Aiming at a Moving Target. Neurodegenerative Diseases 17:6, pages 242-250.
Crossref
Crossref
A.O. Adeniji, P.W. Adams & V.V. Mody. 2017. Drug Discovery Approaches for the Treatment of Neurodegenerative Disorders. Drug Discovery Approaches for the Treatment of Neurodegenerative Disorders
109
143
.
L.P. Kotra & J. Park. 2017. Comprehensive Medicinal Chemistry III. Comprehensive Medicinal Chemistry III
439
473
.
Tsuneya Ikezu. 2017. Neuroimmune Pharmacology. Neuroimmune Pharmacology
753
766
.
Adrian Ivanoiu, Jérémie Pariente, Kevin Booth, Kasia Lobello, Gerald Luscan, Lisa Hua, Prisca Lucas, Scot Styren, Lingfeng Yang, David Li, Ronald S. Black, H. Robert Brashear & Thomas McRae. (2016) Long-term safety and tolerability of bapineuzumab in patients with Alzheimer’s disease in two phase 3 extension studies. Alzheimer's Research & Therapy 8:1.
Crossref
Crossref
Rik Vandenberghe, Juha O. Rinne, Mercè Boada, Sadao Katayama, Philip Scheltens, Bruno Vellas, Michael Tuchman, Achim Gass, Jochen B. Fiebach, Derek Hill, Kasia Lobello, David Li, Tom McRae, Prisca Lucas, Iona Evans, Kevin Booth, Gerald Luscan, Bradley T. Wyman, Lisa Hua, Lingfeng Yang, H. Robert Brashear & Ronald S. Black. (2016) Bapineuzumab for mild to moderate Alzheimer’s disease in two global, randomized, phase 3 trials. Alzheimer's Research & Therapy 8:1.
Crossref
Crossref
Knut Biber, Thomas Möller, Erik Boddeke & Marco Prinz. (2015) Central nervous system myeloid cells as drug targets: current status and translational challenges. Nature Reviews Drug Discovery 15:2, pages 110-124.
Crossref
Crossref
Cristina Carvalho, Sónia C. Correia, George Perry, Rudy J. Castellani & Paula I. Moreira. (2015) Cerebrovascular and mitochondrial abnormalities in Alzheimer’s disease: a brief overview. Journal of Neural Transmission 123:2, pages 107-111.
Crossref
Crossref
Elvira Valera, Brian Spencer & Eliezer Masliah. (2015) Immunotherapeutic Approaches Targeting Amyloid-β, α-Synuclein, and Tau for the Treatment of Neurodegenerative Disorders. Neurotherapeutics 13:1, pages 179-189.
Crossref
Crossref
Alexander Alex, C. John Harris, Wilma W. Keighley & Dennis A. Smith. 2015. Attrition in the Pharmaceutical Industry. Attrition in the Pharmaceutical Industry
106
127
.
Heeyoung Kang & Kyung Won Park. (2015) Recent Update of Clinical Drug Trials in Alzheimer’s Disease. Journal of the Korean Neurological Association 33:4, pages 252-258.
Crossref
Crossref
Florindo Stella, Márcia Radanovic, Paulo Renato Canineu, Vanessa J. R. de Paula & Orestes V. Forlenza. (2015) Anti-dementia medications: current prescriptions in clinical practice and new agents in progress. Therapeutic Advances in Drug Safety 6:4, pages 151-165.
Crossref
Crossref
Haruhiko Sugino, Akihito Watanabe, Naoki Amada, Miho Yamamoto, Yuta Ohgi, Dusan Kostic & Raymond Sanchez. (2015) Global Trends in Alzheimer Disease Clinical Development: Increasing the Probability of Success. Clinical Therapeutics 37:8, pages 1632-1642.
Crossref
Crossref
Morgan Robinson, Brenda Yasie Lee & Zoya Leonenko. (2015) Drugs and drug delivery systems targeting amyloid-β in Alzheimer's disease. AIMS Molecular Science 2:3, pages 332-358.
Crossref
Crossref